Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers

Summary

A Phase 1, first in human (FIH), single-centre, double-blind, randomized, placebo-controlled, dose escalating trial to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of CBS001 in healthy subjects. The study will be conducted in 2 parts: Part A: Single ascending intravenous (IV) doses of CBS001 Part B: Multiple ascending IV doses of CBS001

Timeline

Start

2022-04-14

Primary completion

2023-08-22

Completion

2023-08-22

Outcome

Outcome not reported

Stopped (Business): “Portfolio reprioritization”

Drugs

Indications

No indication recorded.